Page last updated: 2024-11-05

proflavine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Proflavine is a synthetic acridine dye with antibacterial and antiviral properties. It is typically synthesized by reacting 2,4-diaminotoluene with benzaldehyde in the presence of an oxidizing agent. Proflavine works by intercalating into DNA, disrupting its replication and transcription processes, thereby inhibiting bacterial growth. It has been used historically as a topical antiseptic and disinfectant. Its importance lies in its broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria, as well as its ability to inhibit the growth of viruses like influenza. Research into proflavine focuses on exploring its potential therapeutic applications, particularly in the development of new antimicrobial agents, and investigating its mechanisms of action. Studies are also underway to determine its efficacy in combination with other antimicrobial drugs to enhance their therapeutic potential.'

Proflavine: Topical antiseptic used mainly in wound dressings. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3,6-diaminoacridine : An aminoacridine that is acridine that is substituted by amino groups at positions 3 and 6. A slow-acting bacteriostat that is effective against many Gram-positive bacteria (but ineffective against spores), its salts were formerly used for treatment of burns and infected wounds. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7099
CHEMBL ID55400
CHEBI ID8452
SCHEMBL ID27386
SCHEMBL ID8149677
MeSH IDM0017666

Synonyms (74)

Synonym
ccris 1244
einecs 202-172-4
3,7-diamino-5-azaanthracene
2,8-diaminoacridinium
isoflav base
hsdb 7071
proflavinum [inn-latin]
proflavine [inn]
2,8-diaminoacridine (european)
ai3-52128
acridine, 3,6-diamino-
proflavina [inn-spanish]
brn 0166050
AKOS005449844
NCIMECH_000209
NCI60_004643
NCI60_032077
NCI60_004767
AE-562/12222295 ,
3,6-diaminoacridine
3,6-acridinediamine hydrochloride
3,6-acridinediamine
acridine-3,6-diamine
proflavin
PRL ,
92-62-6
proflavine
1BCU
DB01123
1QVT
1QVU
2,8-diaminoacridine
NCGC00166245-01
bdbm12590
(6-aminoacridin-3-yl)amine;sulfuric acid;hydrate
STK380650
CHEBI:8452 ,
proflavinum
proflavina
wdvshhcdhljjjr-uhfffaoysa-
inchi=1/c13h11n3/c14-10-3-1-8-5-9-2-4-11(15)7-13(9)16-12(8)6-10/h1-7h,14-15h2
CHEMBL55400
NCGC00166245-02
unii-cy3rnb3k4t
5-22-11-00322 (beilstein handbook reference)
cy3rnb3k4t ,
profura
progarmed
AB00375967-03
SCHEMBL27386
2V57
proflavine [hsdb]
proflavine [vandf]
proflavine [who-dd]
proflavine [mi]
SCHEMBL8149677
DTXSID9043776
proflavine (hemisulfate)
AB00375967_04
sr-01000883943
SR-01000883943-1
proflavin hemisulfate;3,6-diaminoacridine hemisulfate
Q420454
CS-0013756
3,6-diaminoacridin
CCG-339542
mfcd00005030
proflavine-hemisulfate
proflavine;3,6-diaminoacridine
AT13412
A909942
YSCH0132
S5776
HY-B1741

Research Excerpts

Overview

Proflavine is a small molecule that intercalates into DNA and, thereby, acts as an anticancer agent. It has potential application to fields such as chemotherapy, photobiology and solar-energy conversion.

ExcerptReferenceRelevance
"Proflavine is an acridine derivative which was discovered as one of the earliest antibacterial agents, and it has been proven to have potential application to fields such as chemotherapy, photobiology and solar-energy conversion. "( Excited-State Dynamics of Proflavine after Intercalation into DNA Duplex.
Chen, J; Jia, M; Jia, Y; Pan, H; Sun, Z; Wang, X; Zhou, J, 2022
)
2.46
"Proflavine is an acridine dye used with high-resolution microendoscopy for in vivo diagnostic evaluation of cervical epithelial cells. "( Is Proflavine Exposure Associated with Disease Progression in Women with Cervical Dysplasia? A Brief Report.
Castle, PE; Cherry, K; Fregnani, JHTG; Hunt, B; Longatto-Filho, A; Pantano, N; Parra, S; Possati-Resende, JC; Richards-Kortum, R; Schmeler, K; Schwarz, RA, 2018
)
2.54
"Proflavine is a small molecule that intercalates into DNA and, thereby, acts as an anticancer agent. "( Structure and dynamics of proflavine association around DNA.
Mukherjee, A; Sasikala, WD, 2016
)
2.18
"Proflavine lotion is a commonly used topical antiseptic in the tropics, but its sensitizing potential was never emphasized and many who developed allergic contact dermatitis were never aware of it. "( Contact sensitivity to proflavine.
Goh, CL, 1986
)
2.02

Treatment

Proflavine did not reduce the rate of reactivation of latent virus and did not increase the average latent period of the treated cultures. Treatment with proflavine resulted in higher transformation frequencies than were found with quinacrine.

ExcerptReferenceRelevance
"Proflavine treatment did not reduce the rate of reactivation of latent virus and did not increase the average latent period of the treated cultures."( Photoinactivation of latent herpes simplex virus in rabbit kidney cells.
Kelleher, JJ; Varani, J, 1976
)
0.98
"Treatment with proflavine resulted in higher transformation frequencies than were found with quinacrine."( Morphological transformation, DNA strand separation, and antinucleoside immunoreactivity following exposure of cells to intercalating drugs.
Bases, R; Elequin, F; Hsu, KC; Liebeskind, D; Mendez, F; Neubort, S, 1982
)
0.6

Toxicity

ExcerptReferenceRelevance
" The possibility of using PA for water disinfection depends on the ratio of safe and effective concentrations."( [Comparative toxicity of photosensitizers in varying destruction].
Beliaeva, NN; Golovach, EN; Kuznetsova, NA; Poliakova, EE; Sinitsina, OO; Sycheva, LP; Zholdakova, ZI,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" dosing, plasma concentration-time profiles of parent PRO and ACR were best described by two- and three-compartment pharmacokinetic models respectively."( Pharmacokinetics, tissue distribution and metabolism of acriflavine and proflavine in the channel catfish (Ictalurus punctatus).
Bencsath, FA; el Said, KR; Hayton, WL; Musser, SM; Plakas, SM, 1998
)
0.53

Bioavailability

ExcerptReferenceRelevance
" The exposures were performed at net forward powers of 500 or 600 W, resulting in a specific absorption rate (SAR) of approximately 40 W/kg."( Proflavin and microwave radiation: absence of a mutagenic interaction.
Eagan, P; Erwin, DN; Meltz, ML, 1990
)
0.28
" PRO and ACR were poorly absorbed in catfish during waterborne exposure."( Pharmacokinetics, tissue distribution and metabolism of acriflavine and proflavine in the channel catfish (Ictalurus punctatus).
Bencsath, FA; el Said, KR; Hayton, WL; Musser, SM; Plakas, SM, 1998
)
0.53

Dosage Studied

ExcerptRelevanceReference
" All of these drugs were able to induce rapid loss of dhfr gene dosage in the R500 cell population."( Drug-induced loss of unstably amplified genes.
Snapka, RM; Wani, MA, 1990
)
0.28
") dosing (1 mg/kg) or waterborne exposure (10 mg/l for 4 h)."( Pharmacokinetics, tissue distribution and metabolism of acriflavine and proflavine in the channel catfish (Ictalurus punctatus).
Bencsath, FA; el Said, KR; Hayton, WL; Musser, SM; Plakas, SM, 1998
)
0.53
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antiseptic drugA substance used locally on humans and other animals to destroy harmful microorganisms or to inhibit their activity (cf. disinfectants, which destroy microorganisms found on non-living objects, and antibiotics, which can be transported through the lymphatic system to destroy bacteria within the body).
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
chromophoreThe part (atom or group of atoms) of a molecular entity in which the electronic transition responsible for a given spectral band is approximately localized.
intercalatorA role played by a chemical agent which exhibits the capability of occupying space between DNA base pairs due to particular properties in size, shape and charge. Intercalation of chemical compounds in DNA helix can result in replication errors (shift, mutation) or DNA damages.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
aminoacridinesAcridines which are substituted in any position by one or more amino groups or substituted amino groups. Note that the term 'aminoacridine' is the International Prorietary Name (INN) for 9-aminoacridine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency28.18380.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency19.95260.016525.307841.3999AID602332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
huntingtin isoform 2Homo sapiens (human)Potency12.58930.000618.41981,122.0200AID1688
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency44.66840.010323.856763.0957AID2662
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency15.84890.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency11.88560.004611.374133.4983AID624296
DNA polymerase kappa isoform 1Homo sapiens (human)Potency9.46620.031622.3146100.0000AID588579
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency11.21170.005612.367736.1254AID624044
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency31.62280.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency12.58930.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abBetacoronavirus England 1IC50 (µMol)10.00000.00403.43889.5100AID1640022
cystic fibrosis transmembrane conductance regulatorHomo sapiens (human)IC50 (µMol)8.88000.140016.625050.0000AID1224863
ProthrombinHomo sapiens (human)IC50 (µMol)12.00000.00000.710710.0000AID1796917
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)1.16000.00022.45859.9600AID1640021; AID1884017; AID1884018
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain H, ALPHA-THROMBINHomo sapiens (human)Kd530.0000530.0000530.0000530.0000AID977611
Chain A, Transcriptional regulator qacRStaphylococcus aureusKd38.500035.000038.500042.0000AID977611
Chain A, Transcriptional regulator qacRStaphylococcus aureusKd38.500035.000038.500042.0000AID977611
Chain A, TETR FAMILY TRANSCRIPTIONAL REPRESSOR LFRRMycolicibacterium smegmatisKd0.07900.07900.07900.0790AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (33)

Processvia Protein(s)Taxonomy
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (86)

Assay IDTitleYearJournalArticle
AID1145949Binding affinity to calf thymus DNA assessed as decrease in DNA sedimentation coefficient at 20 x 10'-6 M relative to untreated control1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
Synthesis and biological properties of some spin-labeled 9-aminoacridines.
AID46134Inhibitory concentration against ethidium:Calf thymus DNA (1.26:1) at pH 5; Measurement not possible due to ligand fluorescence1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID295904Antipromastigote activity against Leishmania infantum2007European journal of medicinal chemistry, Oct, Volume: 42, Issue:10
Synthesis and antileishmanial activity of 6-mono-substituted and 3,6-di-substituted acridines obtained by acylation of proflavine.
AID420946Phototoxicity in transformed CHO cells after 24 hrs of UV irradiation by WST1 assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Photo-inducible cytotoxic and clastogenic activities of 3,6-di-substituted acridines obtained by acylation of proflavine.
AID572151Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomegaydhE plasmid containing Escherichia coli multidrug efflux pump YdhE after 18 to 24 hrs by two fold dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID10004Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID1324527Binding affinity to birch major pollen allergen Bet v 1-A assessed as binding constant at 1H-6 resonance by (1)H relaxation dispersion NMR spectroscopy2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Measurement of Ligand-Target Residence Times by
AID214991Compound is evaluated for trypanocidal activity against Trypanosoma brucei, by exposing the parasites directly to compound prior to injection to mice at 10 E-6 M concentration (pre) in presence of light.1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Identification of an acridine photoaffinity probe for trypanocidal action.
AID45399Cross resistance of chinese hamster cells resistant to actinomycin D as log of ratio of molar concentration of compound inducing 50% inhibition of growth in resistant and sensitive cells1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID677444Binding affinity to AATT DNA by SPR analysis2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
High DNA affinity of a series of peptide linked diaromatic guanidinium-like derivatives.
AID420951Clastogenic activity in CHOK1 cells assessed as lowest drug concentration required to increase number of micronucleated cells after 3 hrs incubation in dark by micronucleus assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Photo-inducible cytotoxic and clastogenic activities of 3,6-di-substituted acridines obtained by acylation of proflavine.
AID214995Compound is evaluated for trypanocidal activity against Trypanosoma brucei, by exposing the parasites directly to compound prior to injection to mice at 10 E-7 M concentration in presence of light1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Identification of an acridine photoaffinity probe for trypanocidal action.
AID10007Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID212744Inhibition of telomerase before assembly using recombinant Tetraymena thermophilia TR and TERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID1884017Inhibition of SARS-CoV-2 papain-like protease using RLRGG-AMC as substrate2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID214987Compound is evaluated for trypanocidal activity against Trypanosoma brucei, by exposing the parasites directly to compound prior to injection to mice at 10 E-5 M concentration in dark conditions1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Identification of an acridine photoaffinity probe for trypanocidal action.
AID225777Inhibitory concentration against ethidium in DNA-binding assay with [poly(dA-dT)]2 (synthetic oligonucleotide)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID1884019Antiviral activity against SARS-CoV-2 infected in human A549 cells expressing ACE2 assessed as viral growth inhibition2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID46169Inhibitory concentration against ethidium:Calf thymus DNA(0.1:1) binding at pH 51997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID98558Concentration required to inhibit the cell growth by 50 % after 48 hr in L1210 leukemic cells.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID46137Inhibitory concentration against ethidium:Calf thymus DNA(1.26:1) binding at pH 7; Measurement not possible due to ligand fluorescence1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID214989Compound is evaluated for trypanocidal activity against Trypanosoma brucei, by exposing the parasites directly to compound prior to injection to mice at 10 E-5 M concentration in presence of lightin1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Identification of an acridine photoaffinity probe for trypanocidal action.
AID677446Binding affinity to (GC)4 DNA by SPR analysis2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
High DNA affinity of a series of peptide linked diaromatic guanidinium-like derivatives.
AID295907Specificity index, Ratio of IC50 for human THP1 to IC50 for Leishmania infantum2007European journal of medicinal chemistry, Oct, Volume: 42, Issue:10
Synthesis and antileishmanial activity of 6-mono-substituted and 3,6-di-substituted acridines obtained by acylation of proflavine.
AID98563Cytotoxic potency required to inhibit L1210 cell growth by 50% after cell drug contact for 48 hrs1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID644953Binding affinity to human pre-hsa-mir-155 miRNA assessed as inhibition of dicer-catalysed (33P)-labelled pre-miRNA processing at 1 mM after 1 hr by PAGE analysis2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Pre-microRNA binding aminoglycosides and antitumor drugs as inhibitors of Dicer catalyzed microRNA processing.
AID1884023Cytotoxicity against African green monkey Vero cells assessed as cell viability2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID214990Compound is evaluated for trypanocidal activity against Trypanosoma brucei, by exposing the parasites directly to compound prior to injection to mice at 10 E-6 M concentration (pre) in dark conditions1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Identification of an acridine photoaffinity probe for trypanocidal action.
AID214992Compound is evaluated for trypanocidal activity against Trypanosoma brucei, by exposing the parasites directly to compound prior to injection to mice at 10 E-6 M concentration in dark conditions1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Identification of an acridine photoaffinity probe for trypanocidal action.
AID214984Compound is evaluated for trypanocidal activity against Trypanosoma brucei, by exposing the parasites directly to compound prior to injection to mice at 10 E-4 M concentration in presence of light1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Identification of an acridine photoaffinity probe for trypanocidal action.
AID1161621Binding affinity to (AT)4 DNA hairpin sequence (unknown origin) by SPR assay2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Unexpected DNA affinity and sequence selectivity through core rigidity in guanidinium-based minor groove binders.
AID660264Ratio of MIC for wild type Escherichia coli HS414 to MIC for acrB-deficient Escherichia coli HS832 by agar dilution method2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID212743Inhibition of telomerase after assembly using recombinant Tetraymena thermophilia TR and TERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID1161620Binding affinity to AATT DNA hairpin sequence (unknown origin) by SPR assay2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Unexpected DNA affinity and sequence selectivity through core rigidity in guanidinium-based minor groove binders.
AID295905Cytotoxicity against human THP1 cells2007European journal of medicinal chemistry, Oct, Volume: 42, Issue:10
Synthesis and antileishmanial activity of 6-mono-substituted and 3,6-di-substituted acridines obtained by acylation of proflavine.
AID1324520Binding affinity to bovine trypsin assessed as ligand-target residence time at 1H-4/5 resonance by (1)H relaxation dispersion NMR spectroscopy2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Measurement of Ligand-Target Residence Times by
AID55630Induced change in DNA-melting (deltaTm) with [poly(dA-dT)]2 at pH 65.01995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID152935Cytotoxic effect in human peripheral blood monocyte cells(PBMC)1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
HIV-1 neutralization and tumor cell proliferation inhibition in vitro by simplified analogues of pyrido[4,3,2-mn]thiazolo[5,4-b]acridine marine alkaloids.
AID55500Concentration required to give 50% fluorescence quenching of bound ethidium for [ethidium]: [poly(dA-dT)]2 DNA in ratio of 0.1:1 at pH 51997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID1324535Binding affinity to bovine trypsin assessed as 1H-CPMG relaxation dispersion data changes in presence of indoxyl sulfate by (1)H relaxation dispersion NMR spectroscopy2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Measurement of Ligand-Target Residence Times by
AID212902Inhibition of human telomerase after assembly using recombinant hTR and hTERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID1324526Binding affinity to bovine trypsin assessed as binding constant at 1H-4/5 resonance by (1)H relaxation dispersion NMR spectroscopy2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Measurement of Ligand-Target Residence Times by
AID572147Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBADomeganorM plasmid containing Neisseria gonorrhoeae multidrug efflux pump NorM after 18 to 24 hrs by two fold dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID54989Induced change in DNA-melting (deltaTm) with calf thymus DNA at pH 65.01995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID212741Inhibition of purified telomerase of Euplotes aediculatus at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID55499Concentration required to give 50% fluorescence quenching of bound ethidium for [ethidium]: [(poly dG-dC)]2 DNA in ratio of 0.1:1 at pH 51997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID1884020Cytotoxicity against human A549 cells expressing ACE2 assessed as cell viability2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1884050Antiviral activity against HCoV-OC43 assessed as viral growth inhibition2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1161626Selectivity index, ratio of binding affinity to (AT)4 DNA hairpin sequence (unknown origin) to binding affinity to AATT DNA hairpin sequence (unknown origin)2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Unexpected DNA affinity and sequence selectivity through core rigidity in guanidinium-based minor groove binders.
AID81416Inhibitory effect against HIV-1 in human peripheral blood monocyte cells(PBMC); Not evaluated for HIV-1 inhibition due to high cytotoxicity.1992Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15
HIV-1 neutralization and tumor cell proliferation inhibition in vitro by simplified analogues of pyrido[4,3,2-mn]thiazolo[5,4-b]acridine marine alkaloids.
AID1884049Antiviral activity against MERS-CoV assessed as viral growth inhibition2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID660265Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID1884022Antiviral activity against SARS-CoV-2 infected in African green monkey Vero cells assessed as viral growth inhibition2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID55632Induced change in DNA-melting (deltaTm) with [poly(dG-dC)]2 at pH 65.01995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID214983Compound is evaluated for trypanocidal activity against Trypanosoma brucei, by exposing the parasites directly to compound prior to injection to mice at 10 E-4 M concentration in dark conditions1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Identification of an acridine photoaffinity probe for trypanocidal action.
AID420949Phototoxicity in normal human keratinocytes after 24 hrs of UV irradiation by WST1 assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Photo-inducible cytotoxic and clastogenic activities of 3,6-di-substituted acridines obtained by acylation of proflavine.
AID54658Inhibitory concentration against ethidium in DNA-binding assay1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID23271Partition coefficient (logD7.4)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID54990Change in DNA-melting (deltaTm) with calf thymus DNA at pH 7.01995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID214993Compound is evaluated for trypanocidal activity against Trypanosoma brucei, by exposing the parasites directly to compound prior to injection to mice at 10 E-6 M concentration in presence of light1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Identification of an acridine photoaffinity probe for trypanocidal action.
AID420945Phototoxicity in transformed CHO cells after 24 hrs incubation in dark by WST1 assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Photo-inducible cytotoxic and clastogenic activities of 3,6-di-substituted acridines obtained by acylation of proflavine.
AID1884018Inhibition of SARS-CoV-2 papain-like protease using ISG15-AMC as substrate2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID677445Binding affinity to (AT)4 DNA by SPR analysis2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
High DNA affinity of a series of peptide linked diaromatic guanidinium-like derivatives.
AID212903Inhibition of human telomerase before assembly using recombinant hTR and hTERT at 50 uM2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase.
AID295906Antiamastigote activity against Leishmania infantum2007European journal of medicinal chemistry, Oct, Volume: 42, Issue:10
Synthesis and antileishmanial activity of 6-mono-substituted and 3,6-di-substituted acridines obtained by acylation of proflavine.
AID45401Effect on cross resistance of chinese hamster ovary CHO cells resistant to colchicine (CHRC5)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1884024Selectivity index, ratio of CC50 for African green monkey Vero cells to EC50 for SARS-CoV-2 infected in African green monkey Vero cells2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID1884021Selectivity index, ratio of CC50 for human A549 cells expressing ACE2 to EC50 for SARS-CoV-2 infected in human A549 cells expressing ACE22022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
AID420948Phototoxicity in normal human keratinocytes after 24 hrs incubation in dark by WST1 assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Photo-inducible cytotoxic and clastogenic activities of 3,6-di-substituted acridines obtained by acylation of proflavine.
AID1324521Binding affinity to bovine trypsin assessed as ligand-target residence time at 1H-9 resonance by (1)H relaxation dispersion NMR spectroscopy2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Measurement of Ligand-Target Residence Times by
AID225778Inhibitory concentration against ethidium in DNA-binding assay with [poly(dG-dC)]2 (synthetic oligonucleotide)1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity.
AID572150Antimicrobial activity against AcrAB-deficient Escherichia coli AG100AX harboring pBAD plasmid after 18 to 24 hrs by two fold dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Functional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.
AID1161622Binding affinity to (CG)4 DNA hairpin sequence (unknown origin) by SPR assay2014Journal of medicinal chemistry, Sep-25, Volume: 57, Issue:18
Unexpected DNA affinity and sequence selectivity through core rigidity in guanidinium-based minor groove binders.
AID295908Binding affinity to DNA by DNA-methyl green bioassay2007European journal of medicinal chemistry, Oct, Volume: 42, Issue:10
Synthesis and antileishmanial activity of 6-mono-substituted and 3,6-di-substituted acridines obtained by acylation of proflavine.
AID209937Minimal bacteriostatic concentration against streptococcus pyogenes under conditions of pH 7.3, 37 degree C; 1 in 1600001982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Fourth Smissman Award Address. The long search for valid structure-action relationships in drugs.
AID26757DNA binding dissociation constant as KD; No data1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Interactions of antitumor drugs with natural DNA: 1H NMR study of binding mode and kinetics.
AID214994Compound is evaluated for trypanocidal activity against Trypanosoma brucei, by exposing the parasites directly to compound prior to injection to mice at 10 E-7 M concentration in dark conditions1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
Identification of an acridine photoaffinity probe for trypanocidal action.
AID487001Binding affinity to calf thymus DNA assessed as change in melting temperature by UV spectrophotometer analysis2010Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12
Study of benzo[a]phenazine 7,12-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation.
AID420952Clastogenic activity in CHOK1 cells assessed as lowest drug concentration required to increase number of micronucleated cells after 3 hrs of UV irradiation by micronucleus assay2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Photo-inducible cytotoxic and clastogenic activities of 3,6-di-substituted acridines obtained by acylation of proflavine.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1811Experimentally measured binding affinity data derived from PDB2004The EMBO journal, Aug-04, Volume: 23, Issue:15
Structural mechanism of the simultaneous binding of two drugs to a multidrug-binding protein.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2004The EMBO journal, Aug-04, Volume: 23, Issue:15
Structural mechanism of the simultaneous binding of two drugs to a multidrug-binding protein.
AID1796917Thrombin Assay from Article 10.1021/jm050850v: \\Application of Fragment Screening and Fragment Linking to the Discovery of Novel Thrombin Inhibitors.\\2006Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4
Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1998FEBS letters, Mar-27, Volume: 425, Issue:2
X-ray and spectrophotometric studies of the binding of proflavin to the S1 specificity pocket of human alpha-thrombin.
AID1811Experimentally measured binding affinity data derived from PDB1998FEBS letters, Mar-27, Volume: 425, Issue:2
X-ray and spectrophotometric studies of the binding of proflavin to the S1 specificity pocket of human alpha-thrombin.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2009Journal of bacteriology, Dec, Volume: 191, Issue:24
Structural plasticity and distinct drug-binding modes of LfrR, a mycobacterial efflux pump regulator.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (519)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990334 (64.35)18.7374
1990's62 (11.95)18.2507
2000's50 (9.63)29.6817
2010's58 (11.18)24.3611
2020's15 (2.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.94 (24.57)
Research Supply Index6.35 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index70.44 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (2.33%)5.53%
Reviews10 (1.79%)6.00%
Case Studies10 (1.79%)4.05%
Observational0 (0.00%)0.25%
Other526 (94.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (19)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of Low-Cost High Resolution Microendoscope for the Detection of Lower Gastrointestinal Neoplasia [NCT01384240]Early Phase 1183 participants (Actual)Interventional2010-04-30Terminated(stopped due to Study is closed as the PI transferred to another institution.)
A Pilot Study of a Low-Cost Optical Imaging Tool for Cervical Cancer Screening in Brazil [NCT02335372]300 participants (Actual)Interventional2013-06-30Completed
Evaluation of a Miniaturized Microscope Device for the Detection of Barrett's Neoplasia: A Pilot Study [NCT01384227]Early Phase 140 participants (Actual)Interventional2009-02-28Completed
Endoscopic Multispectral Imaging for the Early Detection of Gastric Neoplasia [NCT02207959]Phase 18 participants (Actual)Interventional2015-01-31Terminated(stopped due to PI left institution)
High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia: A Randomized, Multicenter Trial of Accuracy, Yield, and Clinical Impact [NCT02029937]Phase 21,300 participants (Anticipated)Interventional2014-01-31Recruiting
Use of Fluorescence Imaging and High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection in Patients With Endometrial Cancer [NCT02095847]Phase 20 participants (Actual)InterventionalWithdrawn
A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia - Project 1 [NCT01384695]Early Phase 167 participants (Actual)Interventional2009-06-30Terminated(stopped due to Low/no enrollment. No subjects were enrolled over the past year.)
Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer [NCT01384708]Early Phase 170 participants (Actual)Interventional2010-08-31Completed
Endoscopic Multispectral Imaging for the Early Detection of Barrett's Neoplasia [NCT01384864]Early Phase 130 participants (Actual)Interventional2011-08-31Completed
The Effectiveness of High Resolution Microendoscopy (HRME) in High Grade Intraepithelial Lesions (HSIL) Diagnosis for People Living With HIV [NCT04563754]Phase 1/Phase 2161 participants (Actual)Interventional2019-07-30Completed
Precision Optical Guidance for Oral Biopsy Based on Next-Generation Hallmarks of Cancer (1R01DE029590-01): A Clinical Study to Evaluate and Optimize the Technical Performance Characteristics of an Active Biopsy Guidance System [NCT05554133]90 participants (Anticipated)Interventional2023-06-15Recruiting
Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening: A Clinical Study in Brazil [NCT05396781]Phase 241 participants (Actual)Interventional2022-01-13Completed
Accuracy, Yield and Clinical Impact of a Low-Cost High Resolution Microendoscope in the Early Diagnosis of Esophageal Adenocarcinoma [NCT02018367]Phase 2100 participants (Anticipated)Interventional2012-09-30Recruiting
Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley [NCT02714439]Early Phase 1150 participants (Anticipated)Interventional2016-10-25Active, not recruiting
Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix [NCT02206048]9 participants (Actual)Interventional2015-10-02Completed
Wide-Field and High Resolution In Vivo Imaging of Oral Neoplasia Using Topical Fluorescent Dyes: A Feasibility Study [NCT01269190]Early Phase 1275 participants (Anticipated)Interventional2010-12-30Recruiting
Multimodal Imaging for Surveillance of Patients With Oral Potentially Malignant Disorders [NCT02790853]Early Phase 1600 participants (Anticipated)Interventional2016-05-25Recruiting
In Vivo Multimodal Imaging of Upper Aerodigestive Epithelia [NCT01456143]33 participants (Actual)Interventional2011-12-31Terminated(stopped due to PI left, study to be re-open with new PI, no planned data analysis)
Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia [NCT02420665]Early Phase 150 participants (Actual)Interventional2015-09-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01456143 (6) [back to overview]Accuracy
NCT01456143 (6) [back to overview]Interrater Reliability
NCT01456143 (6) [back to overview]Negative Predictive Value
NCT01456143 (6) [back to overview]Positive Predictive Value
NCT01456143 (6) [back to overview]Sensitivity
NCT01456143 (6) [back to overview]Specificity

Accuracy

Accuracy of reviewers in differentiating neoplastic or benign mucosa in comparison to the pathology results (NCT01456143)
Timeframe: Immediately following image (day of enrollment or up to 2 weeks after enrollment)

InterventionPercent of images with correct diagnosis (Mean)
HRME With Proflavine95.1

[back to top]

Interrater Reliability

Amount of agreement among the 11 blinded head and neck cancer specialists, determined by the Fleiss Kappa. 33 benign and 65 cancer images were evaluated by the reviewers who were blinded to the anatomical site, tumor subsite, and final histopathologic diagnosis. Each reviewer was asked to classify each image as benign or neoplastic. The reviewers evaluated the images based on nuclear size, nuclear to cytoplasmic ratio, and overall cell architecture. Images were randomized in their presentation to the reviewers as to not establish any pattern. Each reviewer provided their interpretation in isolated settings to avoid influence from other reviewers. (NCT01456143)
Timeframe: Immediately following image (day of enrollment or up to 2 weeks after enrollment)

Interventionproportion of agreement among 11 experts (Number)
HRME With Proflavine.81

[back to top]

Negative Predictive Value

NPV = proportion of those with a negative test without neoplasia compared to pathology results (NCT01456143)
Timeframe: Immediately following image (day of enrollment or up to 2 weeks after enrollment)

InterventionPercent of images with correct diagnosis (Mean)
HRME With Proflavine98

[back to top]

Positive Predictive Value

PPV = proportion of those with a positive test who have neoplasia compared to pathology results (NCT01456143)
Timeframe: Immediately following image (day of enrollment or up to 2 weeks after enrollment)

InterventionPercent of images with correct diagnosis (Mean)
HRME With Proflavine91

[back to top]

Sensitivity

Sensitivity = probability that the HRME correctly classifies as positive those with neoplasia compared to pathology results (NCT01456143)
Timeframe: Immediately following image (day of enrollment or up to 2 weeks after enrollment)

InterventionPercent of images with correct diagnosis (Mean)
HRME With Proflavine96

[back to top]

Specificity

Specificity = Probability that the HRME correctly classifies as negative those without neoplasia compared to pathology results (NCT01456143)
Timeframe: Immediately following image (day of enrollment or up to 2 weeks after enrollment)

InterventionPercent of images with correct diagnosis (Mean)
HRME With Proflavine95

[back to top]